Stefano Spolitu1, Haruka Okamoto2, Wen Dai1, John A Zadroga1, Erika S Wittchen3, Jesper Gromada2, Lale Ozcan1. 1. From the Department of Medicine, Columbia University, New York (S.S., W.D., J.A.Z., L.O.). 2. Regeneron Pharmaceuticals, Inc, Tarrytown, NY (H.O., J.G.). 3. Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill (E.S.W.).
Abstract
RATIONALE: Glucagon is a key hormone that regulates the adaptive metabolic responses to fasting. In addition to maintaining glucose homeostasis, glucagon participates in the regulation of cholesterol metabolism; however, the molecular pathways underlying this effect are incompletely understood. OBJECTIVE: We sought to determine the role of hepatic Gcgr (glucagon receptor) signaling in plasma cholesterol regulation and identify its underlying molecular mechanisms. METHODS AND RESULTS: We show that Gcgr signaling plays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through regulating the PCSK9 (proprotein convertase subtilisin/kexin type 9) levels. Silencing of hepatic Gcgr or inhibition of glucagon action increased hepatic and plasma PCSK9 and resulted in lower LDLR (LDL receptor) protein and increased plasma LDL-C. Conversely, treatment of wild-type (WT) mice with glucagon lowered LDL-C levels, whereas this response was abrogated in Pcsk9-/- and Ldlr-/- mice. Our gain- and loss-of-function studies identified Epac2 (exchange protein activated by cAMP-2) and Rap1 (Ras-related protein-1) as the downstream mediators of glucagon's action on PCSK9 homeostasis. Moreover, mechanistic studies revealed that glucagon affected the half-life of PCSK9 protein without changing the level of its mRNA, indicating that Gcgr signaling regulates PCSK9 degradation. CONCLUSIONS: These findings provide novel insights into the molecular interplay between hepatic glucagon signaling and lipid metabolism and describe a new posttranscriptional mechanism of PCSK9 regulation.
RATIONALE: Glucagon is a key hormone that regulates the adaptive metabolic responses to fasting. In addition to maintaining glucose homeostasis, glucagon participates in the regulation of cholesterol metabolism; however, the molecular pathways underlying this effect are incompletely understood. OBJECTIVE: We sought to determine the role of hepatic Gcgr (glucagon receptor) signaling in plasma cholesterol regulation and identify its underlying molecular mechanisms. METHODS AND RESULTS: We show that Gcgr signaling plays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through regulating the PCSK9 (proprotein convertase subtilisin/kexin type 9) levels. Silencing of hepatic Gcgr or inhibition of glucagon action increased hepatic and plasma PCSK9 and resulted in lower LDLR (LDL receptor) protein and increased plasma LDL-C. Conversely, treatment of wild-type (WT) mice with glucagon lowered LDL-C levels, whereas this response was abrogated in Pcsk9-/- and Ldlr-/- mice. Our gain- and loss-of-function studies identified Epac2 (exchange protein activated by cAMP-2) and Rap1 (Ras-related protein-1) as the downstream mediators of glucagon's action on PCSK9 homeostasis. Moreover, mechanistic studies revealed that glucagon affected the half-life of PCSK9 protein without changing the level of its mRNA, indicating that Gcgr signaling regulates PCSK9 degradation. CONCLUSIONS: These findings provide novel insights into the molecular interplay between hepatic glucagon signaling and lipid metabolism and describe a new posttranscriptional mechanism of PCSK9 regulation.
Authors: Bin Dong; Minhao Wu; Hai Li; Fredric B Kraemer; Khosrow Adeli; Nabil G Seidah; Sahng Wook Park; Jingwen Liu Journal: J Lipid Res Date: 2010-01-04 Impact factor: 5.922
Authors: Lale Ozcan; Catherine C L Wong; Gang Li; Tao Xu; Utpal Pajvani; Sung Kyu Robin Park; Anetta Wronska; Bi-Xing Chen; Andrew R Marks; Akiyoshi Fukamizu; Johannes Backs; Harold A Singer; John R Yates; Domenico Accili; Ira Tabas Journal: Cell Metab Date: 2012-04-12 Impact factor: 27.287
Authors: Jia C Wang; Jeff Y-J Lee; Sonja Christian; May Dang-Lawson; Caitlin Pritchard; Spencer A Freeman; Michael R Gold Journal: J Cell Sci Date: 2017-02-06 Impact factor: 5.285
Authors: H Ueno; T Shibasaki; T Iwanaga; K Takahashi; Y Yokoyama; L M Liu; N Yokoi; N Ozaki; S Matsukura; H Yano; S Seino Journal: Genomics Date: 2001-11 Impact factor: 5.736
Authors: Brian Finan; Bin Yang; Nickki Ottaway; David L Smiley; Tao Ma; Christoffer Clemmensen; Joe Chabenne; Lianshan Zhang; Kirk M Habegger; Katrin Fischer; Jonathan E Campbell; Darleen Sandoval; Randy J Seeley; Konrad Bleicher; Sabine Uhles; William Riboulet; Jürgen Funk; Cornelia Hertel; Sara Belli; Elena Sebokova; Karin Conde-Knape; Anish Konkar; Daniel J Drucker; Vasily Gelfanov; Paul T Pfluger; Timo D Müller; Diego Perez-Tilve; Richard D DiMarchi; Matthias H Tschöp Journal: Nat Med Date: 2014-12-08 Impact factor: 53.440
Authors: Lale Ozcan; Canan Kasikara; Arif Yurdagul; George Kuriakose; Brian Hubbard; Michael H Serrano-Wu; Ira Tabas Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: Jon R Backstrom; Jinsong Sheng; Michael C Wang; Alexandra Bernardo-Colón; Tonia S Rex Journal: Mol Ther Methods Clin Dev Date: 2020-09-06 Impact factor: 6.698
Authors: Carlota Oleaga; Michael D Shapiro; Joshua Hay; Paul A Mueller; Joshua Miles; Cecilia Huang; Emily Friz; Hagai Tavori; Peter P Toth; Cezary Wójcik; Bruce A Warden; Jonathan Q Purnell; P Barton Duell; Nathalie Pamir; Sergio Fazio Journal: J Am Coll Cardiol Date: 2021-10-05 Impact factor: 24.094